10July

Novo Nordisk successfully completes first phase 3a trial with semaglutide in peo ... Read more

01July

Novo Nordisk to cease distribution of Tresiba® in Germany ... Read more

26June

Levemir® receives positive CHMP opinion for extended use in children as young as ... Read more

24June

In a phase 3 trial, NovoEight® provided long-term efficacy and safety in the pro ... Read more

28July

Team Novo Nordisk, the world's first all-diabetes professional cycling team, to ... Read more

27July

Novo Nordisk A/S - Share repurchase programme ... Read more

20July

Novo Nordisk A/S - Share repurchase programme ... Read more

13July

Novo Nordisk A/S - Share repurchase programme ... Read more

06August

Financial statement for the first six months of 2015,

07August

Q2 presentation London, London

10August

Q2 roadshow North America,

10August

Q2 roadshow Europe,

 

 

 

Investors

 
Share information


Take an advanced view of the Novo Nordisk share

 
IR material


Download relevant Investor Relations material

 
Q2 results


See information on the Q2 release



Novo Nordisk at a glance


Private shareholders


See relevant content for private investors



Annual report


Download the Novo Nordisk Annual Report



Contacts



Subscriptions


Sign up and follow Novo Nordisk Investors Relations



Recent event


See information on the ADA 2015 investor and analyst even